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Introduction: Inflammation is important for lung oncogenesis. Use 
of nonsteroidal anti-inflammatory drugs (NSAIDs) has been shown 
to improve colorectal cancer survival. However, few studies have 
examined the association in lung cancer patients.
Methods: The VITamins And Lifestyle (VITAL) cohort includes 
Washington State residents, aged 50 to 76 years, who completed a 
baseline questionnaire between 2000 and 2002. Participants responded 
on the frequency and duration of use of individual NSAIDs in the 
previous 10 years. Subjects of this study were 785 members of the 
cohort, who were identified with incident lung cancer from baseline 
through 2007 through linkage to a population-based cancer registry. 
Participants were followed for lung cancer death through linkage to 
state records of death through 2009. Adjusted proportional hazards 
models estimated hazard ratios (HR) and 95% confidence intervals 
(CI) for the association between NSAIDs and lung cancer death.
Results: Five hundred and twenty-two participants (66%) died from 
lung cancer. Relative to nonuse, high (≥ 4 days/week and ≥ 4 years) 
prediagnostic use of regular-strength or low-dose aspirin (HR 0.99, 
95% CI: 0.74–1.33 and HR 0.89, 95% CI: 0.67–1.17, respectively) 
or total nonaspirin NSAIDs (HR 1.20, 95% CI: 0.79–1.83) did not 
reduce lung cancer death. However, high use of ibuprofen was asso-
ciated with a 62% increased risk of lung cancer death (HR 1.62, 95% 
CI: 1.01–2.58).
Conclusions: Long-term, prediagnostic NSAID use does not 
improve lung cancer survival overall. Use of ibuprofen may reduce 
survival from lung cancer. Our results underscore the need for fur-
ther study of the mechanisms of action for individual NSAIDs with 
regard to cancer survival.
Key Words: Aspirin, Ibuprofen, Nonsteroidal anti-inflammatory 
drugs, Lung Cancer, Histology, Survival.
(J Thorac Oncol. 2012;7: 1503–1512)
Inflammation is important for lung cancer development and progression.1 We,2 and other prospective studies of nonste-
roidal anti-inflammatory drug (NSAID) use,3 including one 
 randomized trial of aspirin,4 have demonstrated reductions in 
lung cancer risk, although findings have been inconsistent.5–15 
Recently, Rothwell et al.16 published findings from a pooled anal-
ysis of three randomized trials of aspirin and 20-year cancer mor-
tality among men. The authors reported that allocation to aspirin 
versus a placebo was protective for lung cancer death (hazard 
ratio (HR) 0.71, 95% confidence interval (CI): 0.58–0.89).16
There is increasing evidence that use of NSAIDs 
improves survival from colorectal cancer;17,18 however, rela-
tively few studies have examined the association between the 
use of NSAIDs and lung cancer survival.19–24 The majority of 
such studies are randomized trials of NSAIDs in addition to 
chemotherapy in advanced disease; no survival benefit has 
been reported in these trials.19–22,24 The only observational 
study to examine the association between NSAID use and 
lung cancer survival reported that preoperative, regular aspi-
rin use was associated with a 16% reduction in the hazard of 
all-cause mortality (HR 0.84, p- = 0.05).23
Existing studies of mortality or survival are limited. 
Findings from the pooled analysis are difficult to interpret 
because it is unclear as to whether they describe a reduction 
in lung cancer incidence or an improvement in survival after 
diagnosis.16 Clinical trials involving lung cancer patients were 
limited in assessing the role of NSAIDs with survival because 
of small sample sizes (n ≤ 400), scope (i.e., stages at  diagnosis, 
histologic types), outcome (i.e., overall rather than cause- 
specific survival), and NSAID type (typically cyclooxygenase-2 
[COX-2] inhibitors).19–24 None have examined the use of com-
monly available nonaspirin NSAIDs (e.g., ibuprofen). Given 
that two studies of prediagnostic aspirin use reported improve-
ments in lung cancer mortality16 or survival,23 it remains a pos-
sibility that prediagnostic use of aspirin or other NSAIDs may 
improve survival from lung cancer.
Here we present our investigation of the association 
between long-term prediagnostic NSAID use and survival 
from lung cancer among members of the VITamins And 
Lifestyle (VITAL) cohort.
PATIENTS AND METHODS
Study Population
Because we were interested in case fatality rather than 
mortality, we only considered the 851 lung cancer cases 
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diagnosed in the VITAL cohort for our analysis. The VITAL 
cohort is a prospective study designed to investigate the associ-
ations of dietary supplements and medications with cancer risk. 
Details of the study design and cohort enumeration are given 
in the work by White et al.25 Briefly, 77,719 men and women 
aged between 50 and 76 years at baseline, who lived in the 
13-county region in western Washington State covered by the 
Surveillance, Epidemiology, and End Results (SEER) cancer 
registry, answered a baseline questionnaire between October 
2000 and December 2002. All participants gave informed con-
sent and study procedures were approved by the Institutional 
Review Board at the Fred Hutchinson Cancer Research Center.
Cohort members were followed for incident lung can-
cer diagnoses from baseline to December 31, 2007 through 
annual linkage to SEER, which ascertains all cancer cases 
diagnosed within western Washington State, along with data 
on stage and histology. After an average of 6 years of follow-
up, 851 incident lung cancer cases were identified.
Exclusions were made for participants with a positive 
or missing history of lung cancer (n = 32), diagnoses of lung 
lymphoma histology (n = 2), in situ lung cancer (n = 1), and 
lung cancers identified on their death certificate only (n = 8). 
Participants were additionally excluded if data were missing 
regarding their NSAID use (n = 14) or cause of death (n = 9), 
leaving 785 lung cancer cases available for study.
Follow-up for Lung Cancer Death
The 785 members of the VITAL cohort diagnosed with 
incident lung cancer were followed prospectively for lung can-
cer death from the date of diagnosis to December 31, 2009; 
thus the range of follow-up time from diagnosis to end of 
follow-up was 2 to 9 years. Deaths were ascertained by linking 
to the Washington State death file, which includes deaths among 
Washington State residents who died out of state. Underlying 
causes of death were reported and coded using International 
Classifications of Disease, 10th revision (ICD-10).
Censoring
The remaining participants were right-censored from 
the analysis at the earliest date of the following events: death 
from other causes (n = 91); emigration out of the Washington 
State catchment area (n = 17), identification through the 
National Change of Address System and active follow-up; or 
December 31, 2009, the most recent date of linkage to the 
Washington State death file (n = 155).
Data Collection
The baseline questionnaire included questions on par-
ticipants’ regular use of NSAIDs, defined as 1 day or more 
per week for 1 year or more, including frequency (days/week) 
and duration of use (years) in the past 10 years of low-dose 
aspirin, regular or extra-strength aspirin, ibuprofen, naproxen, 
and celecoxib/rofecoxib. Use of each drug over the 10 years 
before baseline was categorized as none; low, less than 4 days 
a week or less than 4 years; and high, 4 days or more per week 
and 4 years or more. Additional variables included nonaspirin 
NSAIDs, defined as the maximum of 10-year use of ibupro-
fen, naproxen, or celecoxib/rofecoxib, and regular-strength 
NSAIDs, defined as the maximum of 10-year use of regular 
or extra-strength aspirin, ibuprofen, naproxen, or celecoxib/
rofecoxib. Both variables were categorized as none, low, and 
high use as for individual NSAIDs. Low-dose aspirin use was 
excluded from the regular-strength NSAIDs variable as it is 
not considered to have strong anti-inflammatory activity.26, 27
Data were also collected at baseline on potential con-
founding factors. Participants reported on their demographic 
and health-related characteristics, including race, education, 
height and weight, physical activity, personal and family med-
ical history, smoking history, and regular diet.
Lung cancer characteristics, including histology, SEER 
summary stage (all years), and American Joint Committee on 
Cancer (AJCC) stage (available for cancers diagnosed after 
2003), were collected from SEER data.
Statistical Analysis
Cox proportional hazards regression models using 
follow-up time from the date of diagnosis as the time variable 
were used to calculate age and sex-adjusted or multivariable-
adjusted HR and 95% CIs for the associations of participant 
characteristics and NSAID use with lung cancer death. We 
selected a priori potential confounders for inclusion in mul-
tivariable models. Proportional hazards models were adjusted 
for known or suspected risk factors of lung cancer survival, 
indications/contraindications of NSAID use, and tumor char-
acteristics (see Table 2). Multivariable models for any one 
NSAID variable were simultaneously adjusted for the other 
NSAID variables. Because AJCC stage was only available 
for lung cancers diagnosed after 2003, models were adjusted 
for SEER summary stage for cancers diagnosed between 
2000 and 2003 and AJCC stage for cancers diagnosed 
between 2004 and 2007. The Spearman correlation coefficient 
between AJCC and SEER summary stage was 0.88, indicat-
ing strong agreement between the measures. Models were 
further adjusted for year of diagnosis (before or during 2003/
after 2003) to account for this difference. p Values for trend 
(p trend) were calculated by treating categorical exposures as 
ordinals in proportional hazards models.
 We stratified analyses to examine whether associa-
tions between the use of NSAIDs and lung cancer death were 
modified by sex, stage at diagnosis, and lung cancer histology. 
p Values for interaction (p interaction) between NSAIDs and 
possible effect-modifiers were calculated by including a mul-
tiplicative term in multivariable models.
All analyses were performed using SAS 9.2 for the PC 
(Cary, NC). All reported p values are two sided.
RESULTS
At the end of follow-up, 613 deaths were observed; 
among the deaths, 522 (85%) were caused by lung cancer. 
The remaining 91 deaths resulted from a variety of causes 
including: coronary heart disease (n = 18), chronic lower 
respiratory disease (n = 13), stroke (n = 6), digestive system 
diseases (n = 5), and other cancers (n = 26), defined as deaths 
from cancers other than breast (n = 3), colorectal (n = 2), 
prostate (n = 1), pancreas (n = 1), hematologic malignan-
cies (n = 5), or lung. Age and sex-adjusted associations of 
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baseline participant characteristics and lung cancer survival 
status are given in Table 1. Among participants diagnosed 
with lung cancer in VITAL, increasing age and male sex 
were positively associated with lung cancer death. Increasing 
pack-years of smoking was associated with elevations in risk 
of lung cancer death and increasing fruit and vegetable con-
sumption were inversely associated with lung cancer death. 
Correlates of NSAID use, including histories of heart dis-
ease, arthritis, or migraine headaches, were not associated 
with lung cancer death.
TABLE 1.  Age, Sex, and Follow-Up Time-Adjusted Associations between Lifestyle and Tumor Characteristics and Lung Cancer 
Survival among 785 VITamins and Lifestyle Participants Diagnosed with Lung Cancer
Characteristic
Lung Cancer Death
Age & Sex-Adjusted
HR (95% CI) of Lung Cancer Death
Yes
n = 522, N (%)
No
n = 263, N (%)
Age at diagnosis (yrs)
50–55.0 16 (72.73) 6 (27.27) 1.00 (reference)
55.1–60.0 36 (64.29) 20 (35.71) 0.94 (0.52–1.69)
60.1–65.0 64 (65.31) 34 (34.69) 0.91 (0.52–1.57)
65.1–70.0 102 (68.00) 48 (32.00) 1.11 (0.65–1.88)
70.1–75.0 141 (65.28) 75 (34.72) 1.00 (0.60–1.69)
75.1–82.4 163 (67.08) 80 (32.92) 1.25 (0.74–2.09)
Sex
Female 322 (73.52) 116 (26.48) 1.00 (reference)
Male 200 (57.64) 147 (42.36) 1.51 (1.26–1.81)
Race
White 481 (66.99) 237 (33.01) 1.00 (reference)
Nonwhite 31 (68.89) 14 (31.11) 1.20 (0.82–1.74)
Education
≤ High school 177 (66.29) 90 (33.71) 1.00 (reference)
Some college 215 (67.61) 103 (32.39) 1.05 (0.86–1.29)
≥ College graduate 121 (67.60) 58 (32.40) 0.99 (0.78–1.25)
Body mass index (kg/m2)
<25.0 178 (63.35) 103 (36.65) 1.00 (reference)
25.0–29.9 220 (70.29) 93 (29.71) 1.06 (0.87–1.30)
≥ 30.0 98 (66.22) 50 (33.78) 1.01 (0.79–1.29)
Pack-years
None 30 (51.72) 28 (48.28) 1.00 (reference)
>0–35.0 155 (63.01) 91 (36.99) 1.37 (0.93–2.04)
35.1–52.5 178 (68.46) 82 (31.54) 1.65 (1.11–2.44)
52.6–135 147 (71.36) 59 (28.64) 1.75 (1.17–2.61)
Self-perceived health
Excellent 29 (65.91) 15 (34.09) 1.00 (reference)
Very good 146 (67.91) 69 (32.09) 1.08 (0.72–1.61)
Good 201 (67.22) 98 (32.78) 1.13 (0.76–1.66)
Fair 111 (66.07) 57 (33.93) 1.23 (0.82–1.86)
Poor 23 (60.53) 15 (39.47) 1.31 (0.75–2.28)
Physical activity (MET-hrs/wk)
None 125 (63.45) 72 (36.55) 1.00 (reference)
>0–3.4 129 (68.62) 59 (31.38) 1.14 (0.89–1.46)
3.5–11.1 124 (65.26) 66 (34.74) 0.96 (0.75–1.24)
11.1–89.0 132 (69.11) 59 (30.89) 1.04 (0.81–1.33)
Fruit and vegetable consumption (servings/day)
0–1.9 162 (71.05) 66 (28.95) 1.00 (reference)
2.0–3.4 158 (68.70) 72 (31.30) 0.88 (0.70–1.09)
3.5–12.7 142 (62.01) 87 (37.99) 0.76 (0.60–0.96)
(Continued)
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TABLE 1. (Continued)
Characteristic
Lung Cancer Death
Age & Sex-Adjusted
HR (95% CI) of Lung Cancer Death
Yes
n = 522, N (%)
No
n = 263, N (%)
History of chronic-obstructive pulmonary disease
No 428 (65.95) 221 (34.05) 1.00 (reference)
Yes 94 (69.12) 42 (30.88) 1.19 (0.95–1.49)
Number of first-degree relatives with lung cancer
None 417 (66.51) 210 (33.49) 1.00 (reference)
1 93 (66.91) 46 (33.09) 0.89 (0.71–1.12)
≥2 10 (71.43) 4 (28.57) 1.38 (0.74–2.60)
History of coronary artery disease
No 427 (66.41) 216 (33.59) 1.00 (reference)
Yes 95 (66.90) 47 (33.10) 1.02 (0.81–1.28)
History of osteoarthritis or chronic joint pain
No 258 (68.07) 121 (31.93) 1.00 (reference)
Yes 264 (65.02) 142 (34.98) 0.99 (0.83–1.17)
History of rheumatoid arthritis
No 486 (66.30) 247 (33.70) 1.00 (reference)
Yes 36 (69.23) 16 (30.77) 1.20 (0.85–1.68)
History of migraine or chronic 
headaches
No 469 (67.00) 231 (33.00) 1.00 (reference)
Yes 53 (62.35) 32 (37.65) 1.12 (0.84–1.50)
History of gastric ulcers
No 463 (66.52) 233 (33.48) 1.00 (reference)
Yes 59 (66.29) 30 (33.71) 1.04 (0.79–1.36)
Tumor histology
Adenocarcinoma 157 (57.72) 115 (42.28) 1.00 (reference)
Squamous cell carcinoma 78 (58.65) 55 (41.35) 0.98 (0.75–1.29)
Large cell carcinoma 13 (76.47) 4 (23.53) 1.54 (0.87–2.71)
Non–small-cell carcinoma, NOS 134 (79.29) 35 (20.71) 2.01 (1.59–2.54)
Small-cell carcinoma 90 (82.57) 19 (17.43) 2.29 (1.75–2.99)
Other 50 (58.82) 35 (41.18) 1.39 (1.01–1.91)
SEER summary stage (2000–2003)
Local 17 (30.91) 38 (69.09) 1.00 (reference)
Regional 43 (64.18) 24 (35.82) 3.14 (1.78–5.56)
Distant 119 (90.84) 12 (9.16) 8.73 (5.14–14.82)
AJCC stage (2004–2007)
I 23 (21.70) 83 (78.30) 1.00 (reference)
II 12 (52.17) 11 (47.83) 3.38 (1.68–6.82)
III 83 (66.94) 41 (33.06) 5.17 (3.24–8.23)
IV 184 (85.58) 31 (14.42) 11.51 (7.39–17.92)
Surgical treatment
No 463 (81.37) 106 (18.63) 1.00 (reference)
Yes 59 (27.31) 157 (72.69) 0.14 (0.10–0.18)
Lymph node resection or aspiration
No 423 (79.81) 107 (20.19) 1.00 (reference)
Yes 98 (38.74) 155 (61.26) 0.22 (0.18–0.28)
Radiation therapy
No 264 (58.15) 190 (41.85) 1.00 (reference)
Yes 253 (78.82) 68 (21.18) 1.61 (1.35–1.93)
Chemotherapy
No 189 (52.65) 170 (47.35) 1.00 (reference)
Yes 324 (78.26) 90 (21.74) 1.60 (1.33–1.92)
HR, hazard ratio; CI, confidence interval; SEER, Surveillance, Epidemiology, and End Results; AJCC, American Joint Committee on Cancer; NOS, not otherwise specified; MET, 
metabolic equivalent of tasks. 
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Associations between SEER-reported tumor characteris-
tics and lung cancer death are additionally presented in Table 1. 
As expected, later stage at diagnosis was strongly predic-
tive of poorer lung cancer survival. In addition, there were 
differences in survival by lung cancer histology, with non– 
small-cell, not otherwise specified (NOS), small-cell carci-
nomas, and other histologies each associated with increases 
in risk of lung cancer death relative to adenocarcinomas. 
Although surgical treatments were associated with reductions 
in risk of lung cancer death and nonsurgical treatments were 
associated with increases in risk of lung cancer death, these 
findings are reflective of mutual confounding and confound-
ing by stage at diagnosis. Each was strongly protective for lung 
cancer death after being placed in a single regression model 
and further adjusted for stage at diagnosis (data not shown).
Table 2 gives age and sex-adjusted and multivariable-
adjusted HRs and 95% CI for the associations between pre-
diagnostic 10-year use of individual NSAIDs and lung cancer 
death. There were few differences between the minimally 
adjusted and fully adjusted models. Compared with nonuse, 
high 10-year use of regular-strength NSAIDs was not associ-
ated with lung cancer death (HR 1.14, 95% CI: 0.87–1.51; 
p trend = 0.10). Use of low-dose or regular-strength aspirin, 
or nonaspirin NSAIDs overall was not associated with lung 
cancer death; however, high 10-year use of ibuprofen was 
associated with a borderline 62% increased risk of lung can-
cer death (HR 1.62, 95% CI: 1.01–2.58; p trend = 0.21). The 
associations did not differ by sex (data not shown).
We hypothesized that NSAIDs may be associated with 
some survival benefit for those diagnosed at earlier stages in 
particular. Therefore, we stratified our analysis on SEER sum-
mary stage (Table 3). Relative to nonuse, high 10-year use of 
regular-strength NSAIDs was not associated with improved 
lung cancer survival for participants whose cancers were 
diagnosed at local/regional (HR 1.12, 95% CI: 0.62–2.03) or 
distant stage (HR 1.11, 95% CI: 0.78–1.59). High use of non-
aspirin NSAIDs was suggestive of an increased risk of lung 
cancer death among those diagnosed at late stage (HR 1.70, 
95% CI: 1.00–2.90; p trend < 0.01). The p value for inter-
action was less than 0.01. Although the nonaspirin NSAIDs 
variable is a combination of several NSAIDs, 17 of 22 partici-
pants classified as high nonaspirin NSAID users among those 
diagnosed with distant stage disease took ibuprofen.
In an exploratory analysis with limited statistical power, 
we additionally stratified analyses on the most common lung 
cancer histologic types (Table 4): Small-cell lung cancer 
(SCLC) (n = 111), adenocarcinoma (n = 275), squamous 
cell carcinoma (n = 133), and non–small-cell lung cancer 
TABLE 2. Associations between NSAID Use and Lung Cancer Death in VITamins and Lifestyle (n = 785)
NSAID
10-Yr Use
p TrendNonuser
Low
(<4 D/Wk or <4 Yrs)
High
(≥4 D/Wk and ≥4 Yrs)
Regular-strength NSAIDsa
Lung cancer deaths, n, yes/no 245/136 131/60 105/50
HR (95% CI) for lung cancer deathb 1.00 (reference) 1.19 (0.95–1.48) 1.10 (0.87–1.39) 0.27
HR (95% CI) for lung cancer deathc 1.00 (reference) 1.54 (1.20–1.96) 1.14 (0.87–1.51) 0.10
Regular-strength aspirin
Lung cancer deaths, n, yes/no 351/189 69/31 83/38
HR (95% CI) for lung cancer deathb 1.00 (reference) 1.14 (0.87–1.50) 1.05 (0.81–1.35) 0.53
HR (95% CI) for lung cancer deathc 1.00 (reference) 1.49 (1.10–2.01) 0.99 (0.74–1.33) 0.51
Nonaspirin NSAIDsd
Lung cancer deaths, n, yes/no 356/186 106/50 33/15
HR (95% CI) for lung cancer deathb 1.00 (reference) 1.08 (0.86–1.35) 1.15 (0.79–1.67) 0.37
HR (95% CI) for lung cancer deathc 1.00 (reference) 1.22 (0.94–1.59) 1.20 (0.79–1.83) 0.14
Ibuprofen
Lung cancer deaths, n, yes/no 402/209 73/41 29/6
HR (95% CI) for lung cancer deathb 1.00 (reference) 0.94 (0.72–1.24) 1.65 (1.10–2.47) 0.13
HR (95% CI) for lung cancer deathc 1.00 (reference) 0.96 (0.71–1.30) 1.62 (1.01–2.58) 0.21
Low-dose aspirin
Lung cancer deaths, n, yes/no 323/158 78/50 89/37
HR (95% CI) for lung cancer deathb 1.00 (reference) 0.88 (0.68–1.14) 1.05 (0.82–1.35) 0.94
HR (95% CI) for lung cancer deathc 1.00 (reference) 0.92 (0.68–1.23) 0.89 (0.67–1.17) 0.36
aIncludes regular-strength aspirin, ibuprofen, naproxen, and COX-2 inhibitors.
bAdjusted for age at diagnosis and sex.
cAdjusted for age at diagnosis, sex, race, pack-years of smoking, self-perceived health, fruit and vegetable consumption, chronic-obstructive pulmonary disease, family history 
of lung cancer, ulcer, migraine or chronic headaches, osteoarthritis or chronic joint pain, rheumatoid arthritis, coronary artery disease, stage at diagnosis, year of diagnosis, histology, 
surgical treatment, lymph node resection, radiation, chemotherapy, and other NSAIDs.
dIncludes ibuprofen, naproxen, and COX-2 inhibitors.
NSAID, nonsteroidal anti-inflammatory drug; HR, hazard ratio; CI, confidence interval; COX-2, cyclooxygenase-2.
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(NSCLC), NOS (n = 173). Compared with nonuse, high 
10-year use of regular-strength NSAIDs was associated 
with a more than threefold increase in the risk of death from 
SCLC (HR 3.33, 95% CI: 1.05–10.52; p trend = 0.03) and not 
associated with survival from the other histologic types. The 
increase in SCLC deaths was because of positive associations 
with both regular-strength aspirin (HR 4.13, 95% CI: 1.28–
13.30; p trend < 0.01) and nonaspirin NSAIDs (HR 3.24, 95% 
CI: 0.49–21.57; p trend = 0.42). Six of seven participants 
classified as high nonaspirin NSAID users among the SCLC 
group used ibuprofen. Use of low-dose aspirin was not 
associated with survival among those diagnosed with SCLC. 
We additionally observed a positive, although statistically 
nonsignificant association between high use of nonaspirin 
NSAIDs and risk of death from NSCLC, NOS (HR 2.00, 
95% CI: 0.77–5.17; p trend = 0.10). Use of low-dose, but not 
regular-strength, aspirin was associated with an increased risk 
of death from squamous cell carcinoma (HR 3.69, 95% CI: 
1.04–13.17; p trend = 0.34) and a reduced risk of death from 
NSCLC, NOS (HR 0.45, 95% CI: 0.23–0.85; p trend = 0.03). 
p Values for interaction did not achieve statistical significance.
DISCUSSION
In this study of 785 VITAL cohort members diagnosed 
with incident lung cancer, we found little evidence to support 
the hypothesis that long-term prediagnostic use of aspirin or 
TABLE 3.  Multivariable-Adjusted Associations between NSAID Use and Lung Cancer Death, Stratified on Surveillance, 
Epidemiology, and End Results Summary Stage at Diagnosis (n = 785)
NSAID
10-Yr Use
p TrendNonuser Low (<4 D/Wk or < 4 Yr) High (≥ 4 D/Wk and ≥4 Yr)
Regular-strength NSAIDsa
Local/regional stage (n = 353)
Lung cancer deaths, n, yes/no 70/96 40/50 32/37 —
HR (95% CI) for lung cancer deathb 1.00 (reference) 1.79 (1.06–3.03) 1.12 (0.62–2.03) 0.45
Distant stage (n = 419)
Lung cancer deaths, n, yes/no 167/38 90/6 69/13 —
HR (95% CI) for lung cancer deathb 1.00 (reference) 1.81 (1.34–2.45) 1.11 (0.78–1.59)
p interaction = 0.08
0.10
Regular-strength aspirin
Local/regional stage (n = 353)
Lung cancer deaths, n, yes/no 103/139 21/26 22/26 —
HR (95% CI) for lung cancer deathb 1.00 (reference) 1.04 (0.57–1.88) 0.89 (0.47–1.69) 0.79
Distant stage (n = 419)
Lung cancer deaths, n, yes/no 239/46 48/3 57/12 —
HR (95% CI) for lung cancer deathb 1.00 (reference) 1.71 (1.17–2.51) 0.89 (0.61–1.30)
p interaction = 0.29
0.79
Nonaspirin NSAIDsc
Local/regional stage (n = 353)
Lung cancer deaths, n, yes/no 101/131 34/42 14/12 —
HR (95% CI) for lung cancer deathb 1.00 (reference) 1.42 (0.86–2.35) 0.79 (0.36–1.74) 0.80
Distant stage (n = 419)
Lung cancer deaths, n, yes/no 242/51 71/5 19/3 —
HR (95% CI) for lung cancer deathb 1.00 (reference) 1.50 (1.07–2.11) 1.70 (1.00–2.90)
p interaction < 0.01
<0.01
Low-dose aspirin
Local/regional stage (n = 353)
Lung cancer deaths, n, yes/no 94/121 26/36 24/26 —
HR (95% CI) for lung cancer deathb 1.00 (reference) 0.49 (0.27–0.89) 0.95 (0.53–1.71) 0.45
Distant stage (n = 419)
Lung cancer deaths, n, yes/no 219/34 52/12 61/10 —
HR (95% CI) for lung cancer deathb 1.00 (reference) 1.12 (0.78–1.62) 0.80 (0.57–1.13)
p interaction = 0.35
0.32
aIncludes regular-strength aspirin, ibuprofen, naproxen, and COX-2 inhibitors.
bAdjusted for age at diagnosis, sex, race, pack-years of smoking, self-perceived health, fruit and vegetable consumption, chronic-obstructive pulmonary disease, family history of 
lung cancer, ulcer, migraine or chronic headaches, osteoarthritis or chronic joint pain, rheumatoid arthritis, coronary artery disease, AJCC stage at diagnosis, year of diagnosis, histol-
ogy, surgical treatment, lymph node resection, radiation, chemotherapy, and other NSAIDs.
cIncludes ibuprofen, naproxen, and COX-2 inhibitors.
NSAID, nonsteroidal anti-inflammatory drug; HR, hazard ratio; CI, confidence interval; COX-2, cyclooxygenase-2; AJCC, American Joint Committee on Cancer.
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nonaspirin NSAIDs improves lung cancer survival. Rather, 
our findings suggest that use of nonaspirin NSAIDs increases 
the risk of lung cancer death among those diagnosed with dis-
tant stage disease, and use of aspirin and nonaspirin NSAIDs 
increases the risk of lung cancer death among those diagnosed 
with SCLC.
Our finding of no association between the use of low-
dose or regular-strength aspirin and lung cancer survival dif-
fers from the literature. In the only previous observational 
study, Fontaine et al.23 examined the association between 
regular aspirin use before surgical resection and overall sur-
vival among 1765 patients with primarily early-stage (89% 
stages I–IIb) NSCLC. The authors reported that aspirin use 
was associated with a 16% reduction in death from all causes 
(HR 0.84, p = 0.05). Fontaine et al.23 did not examine cause- 
specific survival and the authors suggest that their find-
ings may be a result of reductions in cardiovascular disease 
deaths.23 In contrast, in a trial of 303 SCLC patients random-
ized to aspirin (1 g/d) plus chemotherapy versus chemotherapy 
alone, Lebeau et al.24 reported no effect on overall survival.
To our knowledge, no prior study has examined the 
association between ibuprofen or other over-the-counter non-
aspirin NSAIDs and lung cancer survival. The association 
between other nonaspirin NSAIDs, celecoxib (800 mg/d) or 
rofecoxib (50 mg/d) in addition to chemotherapy (e.g., irino-
tecan, docetaxel, and gemcitabine), and lung cancer survival 
have been examined in a few small randomized trials among 
patients diagnosed with late-stage NSCLC;20–22 in contrast to 
our observations of increased risks of lung cancer death, none 
observed an association with survival. In light of the many 
differences between these studies and ours, particularly dif-
ferences in scope (i.e., stages at diagnosis and histologic type) 
and NSAID type, timing, and dose, replication of our finding 
is warranted.
Although limited by statistical power, we additionally 
examined the association between NSAID use and lung can-
cer death by lung cancer histology. Our finding that use of 
regular-strength aspirin and nonaspirin NSAIDs (primarily 
ibuprofen) was associated with three- to fourfold increases in 
risk of lung cancer death among those diagnosed with SCLC 
is not supported by the trial by Lebeau et al.24 described above, 
the only survival study to examine the association between an 
NSAID (aspirin) and survival in SCLC. With the exception 
of NSCLC, NOS, for which we observed an inverse associa-
tion between low-dose aspirin use and lung cancer death, our 
finding of no benefit of NSAID use for NSCLC subtypes is 
largely supported by the clinical trials described above, which 
reported no association in NSCLC patients.19–22 However, in 
the only other observational study of aspirin and overall sur-
vival in NSCLC patients, an inverse association was reported 
with no difference by histologic subtypes.23
Chronic inflammation is thought to be important for the 
development and progression of cancer,28,29 and there is evi-
dence that it is associated specifically with lung oncogenesis.1 
COX enzymes are responsible for the synthesis of prosta-
glandins as a result of cytokine signaling. The inducible COX 
isoform, COX-2 has been associated with cell invasion, angio-
genesis, and metastasis in vitro,1 and its expression in human 
lung cancers has been associated with poorer survival among 
NSCLC patients.30 NSAIDs are thought to inhibit inflamma-
tion by binding to COX-2. In humans, increasing blood con-
centrations of inflammatory biomarkers have been associated 
with poorer lung cancer survival.31–36 Given this evidence, it is 
unclear why long-term prediagnostic use of NSAIDs was not 
associated with a reduction in lung cancer death in this study. 
It is also unclear why some NSAIDs would be associated with 
significant increases in SCLC or late-stage lung cancer deaths. 
We recently reported that NSAID use was inversely associated 
with risk of adenocarcinoma2 and positively associated with 
SCLC risk.37 One possible mechanism may be via modula-
tion of cellular epithelial-mesenchymal transition (EMT). The 
COX-2 pathway has been implicated to play a role in EMT, 
which has been associated with increased cellular migration 
and tumor metastasis.1 Although there is in vitro evidence 
that NSAIDs may reverse EMT in lung cancer,1,38 there are 
also data suggesting that certain NSAIDs can promote EMT 
in lung cancer cell lines, thus enhancing cellular migration.39 
This suggests that NSAIDs may alter tumor behavior, although 
the exact mechanism needs to be further elucidated.
This study has some pertinent limitations that should be 
considered in the evaluation of our results. Foremost, NSAID 
data was collected at baseline, up to 7 years before lung can-
cer diagnosis. Should NSAIDs reduce lung cancer death, 
proper timing of their administration and dosage are not yet 
well understood; however, if we assume that their usage closer 
to time to diagnosis is more important than earlier time peri-
ods,17 nondifferential measurement error would be introduced. 
Depending on its strength, such error may explain the mostly 
null results we observed; however, subgroup findings by tumor 
stage and histology would be in spite of this error. Because we 
were not able to adjust for AJCC stage at diagnosis for cancers 
diagnosed between 2000 and 2003, we are additionally limited 
by incomplete adjustment in regression models. We attempted 
to minimize any residual effect by including SEER summary 
stage as a surrogate for AJCC staging for those years and 
adjusting for AJCC stage among cancers diagnosed after 2003. 
In general, point estimates were not appreciably changed, sug-
gesting that stage at diagnosis and other tumor characteristics 
likely do not lie on the pathway between prediagnostic NSAID 
use and lung cancer death. In addition, NSAID users in this 
study were generally less healthy at baseline and possibly more 
likely to die from causes other than lung cancer than nonus-
ers. These competing risks would have minimal effects on our 
results for two reasons: (1) there were relatively few deaths 
from causes other than lung cancer; and (2) it is unlikely that 
those who died from other causes differed in their risks of lung 
cancer death independent of their shared risk factors, for which 
we made every effort to adjust. Last, given the large number of 
exploratory subgroup analyses, it is possible that these findings 
in particular are the result of chance.
This study has several strengths. It is the first study to 
examine the association between several commonly available 
NSAIDs and lung cancer survival, and the first to examine 
these associations by histologic type, stage, and treatment. 
Our study is the largest in scope, in that we were able to exam-
ine associations in patients with a range of histologies and 
stages at diagnosis. Although limited by the timing of NSAID 
assessment, our baseline questionnaire was comprehensive 
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TABLE 4.  Multivariable-Adjusted Associations between NSAID Use and Lung Cancer Death, Stratified on Lung Cancer 
Histologic Type (n = 785)
NSAID
10-Yr Use
p TrendNonuser Low (<4 D/Wk or < 4 Yr) High (≥4 D/Wk and ≥ 4 Yr)
Regular-strength NSAIDsa
 SCLC (n = 111)
  Lung cancer deaths, n, yes/no 36/8 20/4 23/6 —
  HR (95% CI) for lung cancer deathb 1.00 (reference) 2.27 (0.82–6.29) 3.33 (1.05–10.52) 0.03
 Adenocarcinoma (n = 275)
  Lung cancer deaths, n, yes/no 77/56 46/36 22/15 —
  HR (95% CI) for lung cancer deathb 1.00 (reference) 1.93 (1.21–3.08) 0.80 (0.42–1.52) 0.78
 Squamous cell carcinoma (n = 133)
  Lung cancer deaths, n, yes/no 38/29 16/7 18/18 —
  HR (95% CI) for lung cancer deathb 1.00 (reference) 0.61 (0.19–1.91) 0.88 (0.30–2.58) 0.65
 NSCLC, NOS (n = 173)
  Lung cancer deaths, n, yes/no 64/21 34/6 28/4 —
  HR (95% CI) for lung cancer deathb 1.00 (reference) 1.22 (0.68–2.22) 1.24 (0.69–2.23)
p interaction = 0.89
0.42
Regular-strength aspirin
 SCLC (n = 111)
  Lung cancer deaths, n, yes/no 53/12 13/2 19/5 —
  HR (95% CI) for lung cancer deathb 1.00 (reference) 2.90 (1.06–7.97) 4.13 (1.28–13.30) <0.01
 Adenocarcinoma (n = 275)
  Lung cancer deaths, n, yes/no 111/88 24/14 17/12 —
  HR (95% CI) for lung cancer deathb 1.00 (reference) 1.85 (0.97–3.51) 0.73 (0.35–1.54) 0.89
 Squamous cell carcinoma (n = 133)
  Lung cancer deaths, n, yes/no 51/34 11/6 13/14 —
  HR (95% CI) for lung cancer deathb 1.00 (reference) 0.51 (0.13–1.95) 0.62 (0.19–2.07) 0.37
 NSCLC, NOS (n = 173)
  Lung cancer deaths, n, yes/no 93/26 15/5 24/2 —
  HR (95% CI) for lung cancer deathb 1.00 (reference) 0.86 (0.38–1.90) 0.94 (0.51–1.76)
p interaction = 0.93
0.80
Nonaspirin NSAIDsc
 SCLC (n = 111)
  Lung cancer deaths, n, yes/no 57/13 19/4 6/1
  HR (95% CI) for lung cancer deathb 1.00 (reference) 0.87 (0.26–2.87) 3.24 (0.49–21.57) 0.42
 Adenocarcinoma (n = 275)
  Lung cancer deaths, n, yes/no 106/74 38/31 5/3 —
  HR (95% CI) for lung cancer deathb 1.00 (reference) 1.35 (0.81–2.23) 0.75 (0.24–2.31) 0.64
 Squamous cell carcinoma (n = 133)
  Lung cancer deaths, n, yes/no 54/44 11/6 8/5 —
  HR (95% CI) for lung cancer deathb 1.00 (reference) 0.81 (0.24–2.69) 1.42 (0.39–5.19) 0.75
 NSCLC, NOS (n = 173)
  Lung cancer deaths, n, yes/no 93/29 25/2 10/2 —
  HR (95% CI) for lung cancer deathb 1.00 (reference) 1.40 (0.74–2.63) 2.00 (0.77–5.17)
p interaction = 0.65
0.10
Low-dose aspirin
 SCLC (n = 111)
  Lung cancer deaths, n, yes/no 53/11 14/3 17/4 —
  HR (95% CI) for lung cancer deathb 1.00 (reference) 1.01 (0.33–3.04) 1.23 (0.47–3.22) 0.68
 Adenocarcinoma (n = 275)
  Lung cancer deaths, n, yes/no 97/68 27/29 25/13 —
  HR (95% CI) for lung cancer deathb 1.00 (reference) 0.64 (0.35–1.17) 1.08 (0.61–1.93) 0.70
(Continued)
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with regard to NSAID type and characterization of long-term 
use. In addition, we were able to adjust for many potential 
confounding factors and indications/contraindications of 
NSAID use.
In conclusion, among 785 members of the VITAL cohort 
diagnosed with lung cancer, we found little evidence to support 
the hypothesis that long-term prediagnostic NSAID use is asso-
ciated with an improvement in lung cancer survival. Contrary 
to our hypothesis and current knowledge on mechanisms of 
action, we found that long-term prediagnostic use of nonaspirin 
NSAIDs was associated with a reduction in lung cancer survival 
(i.e., increases in death) among those diagnosed as having late-
stage disease. In addition, use of regular-strength NSAIDs was 
associated with substantial reductions in lung cancer survival 
among those diagnosed with SCLC. Our results underscore the 
need for further study of the timing of use and mechanisms of 
action for individual NSAIDs with regard to cancer survival. 
Because these findings are novel, replication is warranted 
before a clinical recommendation can be made.
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